by 20% indicating reduction of LV filling pressure, the LVEF by Teicholz increased from 30% up to 45% (15%), by Simpson decreased from 45% to 40% by reducing 8.8%, cardiac output decreased from 2.61 l/min to 2.31 l/min during balloon inflation. **Conclusions:** We are reporting the first experience in humans of a new method for intermittent preload reduction in patients with CHF. The beneficial hemodynamic and echocardiographic changes obtained in this patient suggest that this new procedure may play role in the treatment of patients with CHF. Large studies are needed to further evaluate this new procedure.

---

**TCT-429**

**Fetal Pulmonary Valvuloplasty. In-Utero and Post-Natal Outcomes**

Carlos Pedro1, Fabio Peralta1, Rodrigo Costa1, Marcelo Ribeiro1, Jose C. Fernandes1, Carlos R. Ferreiro2, Solange C. Gimenez2, Ieda Jatene2, Simone Pedro1

1Hospital do Coração e Instituto Dante Pazzanese, São Paulo, Brazil, 2Dante Pazzanese, Sao Paulo, Brazil, 3Hospital do Coração e Instituto Dante Pazzanese, Sao Paulo, Brazil, 4Hospital do Coração, Sao Paulo, Brazil

**Background:** There is a paucity of data regarding the feasibility, safety and efficacy of fetal pulmonary valvuloplasty (FPV) for pulmonary atresia or stenosis with intact interventricular septum (PA/PSIVS) and evolving hypoplastic right heart syndrome (HRHS) diagnosed in-utero. We report in-utero and post natal outcomes of this procedure.

**Methods:** FPV was performed under maternal spinal anesthesia and fetal general anesthesia by a multi-disciplinary team under echo monitoring. A 15 cm long 17 G Chiba needle was used to access the apex of the RV. The pulmonary valve (PV) was perforated (when atretic) either with the needle or using a stiff coronary wire. Pre- and post procedural changes in hemodynamic parameters including E/e', TAPSE and LVEF were compared. The procedure was performed by an experience group of 5 cardiologists who in-utero performed 10 FPV procedures. The first group consisted of 3 pediatric cardiologists (2 attending and 1 fellow), the second group of 2 adult cardiologists (1 attending and 1 fellow) and the third group was made of a pediatric cardiologist and an adult cardiologist. All the procedures were reported to the society. The post natal outcomes were reported as well.

**Results:** From 01/08, 10 fetuses (6 PS/ 4 PA; mean age: 27 ± 2 weeks) underwent 11 procedures. There were 2 failures. One had a successful repeated procedure 2 weeks afterwards. There were no maternal complications. The valve was successfully crossed and dilated in 9 with echo evidence of forward flow and pulmonary insufficiency. Ductal spasm was observed in 4. Percardial effusion requiring drainage was observed in all but one patient. One patient was born at elsewhere and underwent a BTT shunt and is now 3 months old. Two fetuses are still in-utero. Six patients were born at our center and underwent neonatal pulmonary valvuloplasty and ductal stenting and were followed over a median post-natal period of 12 months (6–48). In these patients there was a significant and progressive increase in RV size (Z value of the TV, RV length) from the initial in-utero to the last echo assessment and all achieved an eventual BVC and spontaneous closure of the ductal stent with Sats > 90%.

**Conclusions:** FPV followed by neonatal valvuloplasty and ductal stenting was an effective means to achieve RV growth and a BVC in fetuses with PA/PSIVS and evolving HRHS. FPV is technically demanding and frequently results in pericardial effusion requiring drainage. The procedure seems to be safe to the mother. More patients are needed to draw stronger conclusions.

---

**TCT-430**

**A Long Term Lumen Remodeling Analysis of a Novel Non-Drug Eluting Bioabsorbable Stent in Porcine Coronary Arteries**

Carlos A. Gongora1, Masahiko Shibuya1, Kanul Razipoor, Chang Lee1, Jenn McGregor1, Yanping Cheng1, Armando Tellez1, Jose V. Narvaez3, Yizhe Wu1, Li SHEN1, Zhifeng YAO1, Juying Qian1, Xi HU1, Juan XIE2, Junbo GE2

1Cardiovascular Research Foundation, Orangeburg, NY, 2Amarnath Medical, Inc., Mountain View, CA, 3Surgical Center for Cardiovascular Research, Orangeburg, NY, 4CRF, Orangeburg, United States, 5Cardiovascular Research Foundation, Orangeburg, United States

**Background:** Degradation of bioabsorbable stents (BAS) has been shown to allow restoration of the treated segment’s plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent with plasticity and reactivity to those resembling a non-drug eluting stent. We designed the first poly-L-lactic acid (XINSORB scaffold in China. Long-term morphological results of this kind of scaffold were explored in a porcine coronary model.

**Methods:** XINSORB scaffold (3.0mm in diameter and 15mm in length) were implanted into porcine coronary arteries with a reference vessel diameter ranging from 2.5 to 2.8mm, using a 1.1:1 stent-to-artery ratio. Angiogram and optical coherence tomography (OCT) test were performed after implantation and at 1, 3, 12, and 18-month follow-up.

**Results:** Total 28 mini pigs were enrolled and 56 scaffolds were deployed. At 1, 3, 12, and 18-month, 8, 8, 10, and 10 scaffolds were examined respectively. Angiogram after procedure showed that proximal, in-scaffold, and distal minimal lumen diameter were 2.93 ± 0.20mm, 2.78 ± 0.26mm and 2.73 ± 0.30mm. The corresponding percent age of diameter stenosis (%DS) were 5.7 ± 4.0%, 7.0 ± 4.1% and 6.7 ± 4.1% respectively. At 1-month follow-up, proximal, in-scaffold, and distal lumen loss (LLL) of scaffold were 0.53 ± 0.41mm, 0.68 ± 0.42mm and 0.65 ± 0.24mm, while %DS were 9.5 ± 7.7%, 17.6 ± 16.8% and 10.5 ± 7.4%. At 3-month, proximal, in-scaffold, and distal LLL were 0.23 ± 0.48mm, 0.77 ± 0.40mm and 0.11 ± 0.35mm, while %DS were 14.5 ± 9.4%, 31.9 ± 13.6% and 5.4 ± 3.6%. At 12-month, proximal, in-scaffold, and distal LLL were -0.13 ± 0.45mm, 0.28 ± 0.41mm and 0.18 ± 0.48mm, while %DS were 2.4 ± 2.9%, 14.1 ± 9.1% and 8.6 ± 8.7%. At 18-month, proximal, in-scaffold, and distal LLL were 0.37 ± 0.57mm, 0.09 ± 0.31mm and -0.01 ± 0.41mm, while %DS were 3.9 ± 4.6%, 13.7 ± 7.3% and 6.9 ± 5.2%. OCT demonstrated that luminal area, scaffold area, neointimal area and percentage of area stenosis were 5.95 ± 1.63mm2, 8.08 ± 1.16mm2, 2.12 ± 0.67mm2 and 25.8 ± 10.6% at 1 month, 4.02 ± 0.96mm2, 7.91 ± 0.53mm2, 2.98 ± 0.45mm2 and 37.9 ± 19.7% at 3 month, 5.96 ± 0.82mm2, 8.09 ± 0.74mm2, and 2.07 ± 0.36mm2 and 24.1 ± 7.3% at 12 month and 6.84 ± 0.77mm2, 8.74 ± 0.82mm2, 1.94 ± 0.56mm2 and 19.7 ± 6.9% at 18 month. Preserved box of scaffold was 100%, 97.6%, 92.1% and 89.4% at each time point. Conclusions: Neointimal hyperplasia of XINSORB scaffold was prominent at 3-month. After that, LLL and %DS were noticeably reduced. LA at 18-month was significantly larger than that at 3-month with a constant scaffold area.

---

**TCT-432**

**Acute Left Ventricular Unloading and Delayed Coronary Reperfusion Promotes Stromal Cell Derived Factor-1 (SDF-1) Expression and Cardioprotective Signaling in Acute Myocardial Infarction**

Navin K. Kapur1, Vikram Parachar2, Xiaoxing Qiao3, Kevin Morine4, Wajih Syed3, Sam Dow2, Nimesh Shah4, Natesa Pandian4, Richard H. Koras4

1Tufts University, Boston, Massachusetts, 2Tufts Medical Center, Boston, MA

**Background:** Ischemia-reperfusion injury (IRI) remains a major determinant of morbidity in acute myocardial infarction (AMI). Stromal cell-derived factor-1 (SDF-1) is a chemokine that promotes myocardial salvage by activating cardioprotective signaling via Akt, ERK, and STAT-3. No studies have targeted initially reducing left ventricle stroke work (LVSW) to limit IRI in AMI. The Impella CP axial-flow pump reduces LVSW. We tested the hypothesis that first reducing myocardial work and delaying coronary reperfusion reduces infarct size by activating cardioprotective signaling pathways.

**Methods:** AMI was induced by occlusion of the left anterior descending artery (LAD) via angioplasty for 90 minutes in 50kg male Yorkshire swine (n=5/group). In Group 1, the LAD was reperfused for 120 minutes. In Group 2, after 90 minutes of ischemia the Impella CP device was activated and the LAD left occluded for an additional 60 minutes (150 minutes of LAD occlusion total), followed by 120 minutes of reperfusion. The Impella CP was active throughout reperfusion. Western blot analysis quantified myocardial kinase activity.